The Food and Drug Administration approved the Wegovy pill in late December
Discussion In this retrospective secondary analysis of routinely collected clinical data, we compared the efficacy and safety of semaglutide and dulaglutide in newly diagnosed, treatment-nave patients with type 2 diabetes and excess body weight
For people with type 2 diabetes who are also taking insulin or sulfonylureas, the risk is substantially higher and requires active monitoring and likely dose reductions of the diabetes medications as weight and blood glucose improve
The FDAs decision was largely based on data from the SOUL trial, which included data from more than 9,000 patients who were randomized to oral semaglutide or a placebo.[1] All patients had type 2 diabetes in addition to known atherosclerotic cardiovascular disease, chronic kidney disease or both
The Wegovy SmPC advises caution when co-administering with oral medications, especially those where delayed absorption could impact efficacy